Antineoplaston Therapy in Treating Patients With Recurrent or Stage IV Lung Cancer
Status:
Terminated
Trial end date:
2002-05-26
Target enrollment:
Participant gender:
Summary
Current therapies for Recurrent or Stage IV Lung Cancer provide very limited benefit to the
patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove
beneficial in the treatment of Recurrent or Stage IV Lung Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Recurrent or Stage IV Lung Cancer.